Merck Digital Sciences Studio announces launch of 1st cohort

Merck Digital Sciences Studio announces launch of 1st cohort

Merck Digital Sciences Studio, a collaboration between Merck, Microsoft for Startups and the New Jersey Innovation Institute, has officially launched, according to a Friday announcement.

Located in Newark and Cambridge, Massachusetts, the collaborative cohort will focus on important and disruptive biotechnological approaches in artificial intelligence and machine learning, leveraging expertise and tools from clinical scientists to further Merck’s mission to strengthen the life sciences ecosystem.

The 10-month startup accelerator program, with direct investments from Merck Global Health Innovation Fund, Northpond Ventures and McKesson Ventures, plans to empower members and enable the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, networking opportunities with leading partners in the industry and training in an active entrepreneurial setting.

The program includes workshops, mentoring, coaching, subsidized office space and access to Microsoft’s Founders Hub resources, including Azure Cloud computing credits.

The cohort includes:

  • Anderson Biotech: Andson Biotech’s mission is to drive the discovery, development and manufacturing of the next generation of advanced therapies. Its analytical platforms are tailored for modern biopharma process development and control, all the way from laboratory to market.
  • Deep Forest Sciences: Deep Forest Sciences works to make the latest artificial intelligence and machine learning tools for drug discovery accessible to scientists in the biotechnology industry. It uses Chiron to use large scientific foundation models to accelerate the discovery of new molecules, materials, designs and more.
  • is building a conversion rate optimization platform for clinical grade AI. By orchestrating AI-as-a-medical-device, creates the validation infrastructure for robust, safe, and equitable healthcare AI algorithms for all.
  • Magna Labs: Magna Labs provides quality management tools and automation to validate and optimize high-quality bioinformatic software throughout development, accelerating the innovation and delivery of precision science and medicine.
  • IndyGeneUS AI: IndyGeneUS AI accelerates the discovery, development and manufacturing of advanced therapies to address health disparities that African diaspora populations face as they access equitable, high-quality healthcare.
  • Pepper Bio: Pepper Bio has built the world’s first transomics platform to navigate the fastest and safest route to positive patient outcomes. Pepper Bio wants to create a world where there are no untreatable diseases by unraveling complex biology to develop life-saving medicines.
  • SciMar ONE: SciMar’s proprietary technology uses cloud and AI to modernize the manual process of drug development and help pharmaceutical therapies get life-changing therapies to patients faster.
  • Vote Pharm: Stem Pharm improves the clinical translation of neurological drug development by providing physiologically relevant in vitro human models of complex neurological diseases to pharma companies for use in drug discovery and preclinical development.
  • Observe AI: Perceiv AI is an AI-driven precision medicine company developing a powerful multimodal prognostic platform to predict disease progression in age-related diseases such as Alzheimer’s. By providing a window into individual patients’ disease progression, Perceiv AI aims to accelerate and reduce the development of new therapies while enabling more timely diagnoses.

Previous articleInspira adds Salem Medical Center to its healthcare system
Next articleCushman & Wakefield welcomes the next generation of talent to the brokerage roster

Leave a Reply

Your email address will not be published. Required fields are marked *